Evidence map›Paper›PMID 41377991›Full record

ArticleResearch square2025

Gut microbiota phospholipids regulate intestinal gene expression and can counteract the effects of antibiotic treatment.

Martin Blaser, Xue-Song Zhang, Meifan Zhang, Yujue Wang, Haipeng Sun, Matthew Scarnati, Zhan Gao, Yue Yin, Christa Zerbe, Emilia Falcone and 15 more

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Martin BlaserRutgers University.ORCID 0000-0003-2447-2443
Xue-Song ZhangCenter for Advanced Biotechnology and Medicine, Rutgers University.
Meifan ZhangCenter for Advanced Biotechnology and Medicine, Rutgers University.
Yujue WangTsinghua University.
Haipeng SunDepartment of Biochemistry and Microbiology, Rutgers University.
Matthew ScarnatiCenter for Advanced Biotechnology and Medicine, Rutgers University.
Zhan GaoCenter for Advanced Biotechnology and Medicine, Rutgers University.
Yue YinCenter for Advanced Biotechnology and Medicine, Rutgers University.ORCID 0000-0002-5044-7818
Christa ZerbeClinical Center and NIAID, National Institutes of Health.
Emilia FalconeClinical Center and NIAID, National Institutes of Health.
Mary LallyCenter for Advanced Biotechnology and Medicine, Rutgers University.
Jay JoshiCenter for Advanced Biotechnology and Medicine, Rutgers University.
Sneha BhattacharyaCenter for Advanced Biotechnology and Medicine, Rutgers University.
Maria Diaz-RubioMetabolomics Shared Resource, Rutgers Cancer Institute.
Disha BharjCenter for Advanced Biotechnology and Medicine, Rutgers University.
Disha PatelCenter for Advanced Biotechnology and Medicine, Rutgers University.
Samuel PanCenter for Advanced Biotechnology and Medicine, Rutgers University.
Gabrielle RoCenter for Advanced Biotechnology and Medicine, Rutgers University.
Jessica GrenardClinical Center and NIAID, National Institutes of Health.
Abigail ArmstrongCenter for Advanced Biotechnology and Medicine, Rutgers University.
Alexander ValvezanCenter for Advanced Biotechnology and Medicine, Rutgers University.
Steven HollandLaboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.ORCID 0000-0003-3207-5464
Jenifer MulleRutgers University.ORCID 0000-0001-8593-8468
Maria Dominguez-BelloDepartment of Biochemistry and Microbiology, Rutgers University.
Xiaoyang SuRutgers-Robert Wood Johnson Medical School.ORCID 0000-0001-8081-1396

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Adam C Berger · 1997 to 2026
$94.5M
NCI NIH HHS P30 CA072720
6 · The paper itself

Abstract

Early-life antibiotic exposure perturbs the developing gut microbiome and increases risk for immune disorders such as type 1 diabetes (T1D) in non-obese diabetic (NOD) mice. Comparing germ-free and conventional mice, we identified 747 intestinal lipid compounds and defined a subset of gut microbially-produced lipids (GMPLs). Antibiotic treatment disrupted GMPL profiles in mice and in human volunteers, with partial restoration in mice after cecal microbiota transplantation. Among affected compounds, four phospholipids: LPG(13:0), LPG(16:0), LPG(18:0), and PG(15:0_15:0), were structurally defined and tested functionally. These lipids suppressed LPS-induced NFkB activation, modulated innate immune gene expression in intestinal epithelial cells, and enhanced epithelial cell mitochondrial respiration. Oral administration of LPG(16:0) or LPG(18:0) to antibiotic-treated NOD mice partially restored microbiome composition, normalized ileal gene expression, and improved epithelial transport and metabolic pathways. These findings identify bacterial phospholipids as regulators of intestinal immunity and metabolism, with potential therapeutic applications for inflammatory diseases.

Identifiers

PMID41377991
PMCPMC12687810

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.